SCHEDULE: BlackRock Boosts Sarepta Therapeutics Stake to 12.6%

BlackRock, Inc. has reported a 12.6% beneficial ownership stake in Sarepta Therapeutics Inc., holding 13,232,652 shares of common stock as of December 31, 2025.

Summary

• BlackRock, Inc. beneficially owns 13,232,652 shares of Sarepta Therapeutics Inc. common stock.
• This ownership represents 12.6% of Sarepta Therapeutics Inc.'s outstanding common stock.
• BlackRock holds sole voting power over 12,913,969 shares and sole dispositive power over all 13,232,652 shares.
• No shared voting or dispositive power is reported by BlackRock.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Sarepta Therapeutics Inc.
• iShares Core S&P Small-Cap ETF, a BlackRock entity, holds more than 5% of Sarepta Therapeutics Inc.'s common stock.
• BlackRock Fund Advisors, another BlackRock entity, beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant and passive institutional investment by BlackRock in Sarepta Therapeutics Inc. A 12.6% stake from a major asset manager is generally viewed as a positive signal of confidence in the company, even though the filing itself does not provide new operational or financial performance data for the issuer. The 'ordinary course of business' certification reinforces a neutral, long-term investment stance.

Positives

• The significant 12.6% stake held by BlackRock, a major institutional investor, indicates a strong vote of confidence in Sarepta Therapeutics Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic, passive investment rather than speculative trading.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of or with the effect of changing or influencing the control of Sarepta Therapeutics Inc., mitigating risks associated with potential hostile takeovers or activist investor actions.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Sarepta Therapeutics Inc.'s future performance or strategic direction.

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

BlackRock's substantial stake in Sarepta Therapeutics Inc., a company operating in the biotechnology and pharmaceutical sector, highlights continued institutional interest in life sciences. This investment reflects BlackRock's strategy of maintaining diversified portfolios across various industries, including those with high growth potential like biotech.

Comparison to Industry Standards

• BlackRock's 12.6% stake in Sarepta Therapeutics Inc. is a significant position for an institutional investor, often indicating a long-term, passive investment strategy consistent with major asset managers' approaches to core holdings.
• The disclosure of specific underlying funds like iShares Core S&P Small-Cap ETF holding over 5% of the common stock aligns with typical practices for large fund complexes managing diverse investment vehicles.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a reputable firm like BlackRock can enhance investor confidence and potentially stabilize the stock price.
• Management: The passive nature of BlackRock's investment, as stated in the filing, suggests no immediate intent to influence corporate control, allowing current management to continue executing their strategy without external pressure from this specific shareholder.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of BlackRock's significant beneficial ownership in Sarepta Therapeutics Inc. While a 12.6% stake from a major institutional investor is a positive indicator of confidence, the filing does not provide new financial results, operational updates, or strategic guidance for Sarepta Therapeutics Inc. that would warrant a stronger 'buy' or 'sell' recommendation. Investors should consider this information as a data point regarding institutional interest, alongside a comprehensive analysis of Sarepta's fundamentals, industry trends, and future prospects.

Keywords

Sarepta Therapeutics, BlackRock, Institutional Ownership, Common Stock, Schedule 13G, Biotechnology, Pharmaceutical, Asset Management